Neurodegenerative Disease and the NLRP3 Inflammasome
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The prevalence of neurodegenerative disease has increased significantly in recent years, and with a rapidly aging global population, this trend is expected to continue. These diseases are characterised by a progressive neuronal loss in the brain or peripheral nervous system, and generally involve protein aggregation, as well as metabolic abnormalities and immune dysregulation. Although the vast majority of neurodegeneration is idiopathic, there are many known genetic and environmental triggers. In the past decade, research exploring low-grade systemic inflammation and its impact on the development and progression of neurodegenerative disease has increased. A particular research focus has been whether systemic inflammation arises only as a secondary effect of disease or is also a cause of pathology. The inflammasomes, and more specifically the NLRP3 inflammasome, a crucial component of the innate immune system, is usually activated in response to infection or tissue damage. Dysregulation of the NLRP3 inflammasome has been implicated in the progression of several neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and prion diseases. This review aims to summarise current literature on the role of the NLRP3 inflammasome in the pathogenesis of neurodegenerative diseases, and recent work investigating NLRP3 inflammasome inhibition as a potential future therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 1×
“The NLRP3 inflammasome is a multimeric protein complex, which assembles in response to homeostasis-altering molecular patterns (HAMPs), pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), and functions as a centrally important component of the innate immune system (Figure 2…”
BackgroundFeigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602 · cited 1×
“Mitochondria are also key regulators of the NLRP3 inflammasome, with mitochondrial dysfunction resulting in NLRP3 assembly and activation (Zhou et al., 2011; Elliott et al., 2018).”
BackgroundMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“The precise role of these protein aggregates in cell dysfunction, and why they form is still not fully known, but a complex interplay of both environmental and genetic factors are implicated, which impact on several essential cellular processes, including mitochondrial physiology, lysosomal function and autophagy (Fig…”
BackgroundThe NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 4×
“It consists of three main components: an apoptosis-associated speck-like protein containing a CARD (caspase activation and recruitment domain) (ASC), which functions as a central adaptor protein; an inflammatory caspase, caspase-1, and a pattern recognition receptor (PRR) protein, NLRP3 (nucleotide-binding domain (NOD…”
BackgroundInfluentialPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“These protein aggregates are at first found in the neocortex, but, over time, progress to the entorhinal cortex and hippocampus (Thal et al., 2002) (Table 1).”
BackgroundHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 2×
“The genetic ablation of NLRP3 or caspase-1 protected the APP/PS1 mice from spatial memory deficits, reducing brain levels of caspase-1 and IL-1β, as well as enhancing microglial phagocytic ability, thereby increasing Aβ clearance (Heneka et al., 2013).”
BackgroundThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230 · cited 1×
“This result does not directly contradict previous studies highlighting the importance of NLRP3/ASC inflammasome in the production of IL-1β (Agostini et al., 2004; Strowig et al., 2012; Lamkanfi and Dixit, 2014), but does allude to the existence of other potential caspase-1 independent sources of IL-1β production, as s…”
ResultThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895 · cited 1×
“Genome-wide association studies (GWAS) have reported a number of genetic variants, which are associated with an increased risk of developing PD (Zabetian et al., 2007; Pankratz et al., 2009; Satake et al., 2009; Simon-Sanchez et al., 2009; Edwards et al., 2010; Hamza et al., 2010; Saiki et al., 2010; Nalls et al., 201…”
BackgroundBrain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“However, sustained activation of microglia and higher expression of inflammatory molecules, particularly IL-1β, has been found in microglial cells surrounding Aβ plaques, in AD patients as well as animal models of disease (Figure 2) (Griffin et al., 1989; Simard et al., 2006).”
BackgroundAgostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Self-citationPathology of Neurodegenerative Diseases
Dugger, B. N., & Dickson, D. W. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028035 · Cited by 1,665
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506 · cited 2×
“This neurodegenerative condition is caused by a CAG-trinucleotide repeat expansion in the huntingtin gene (HTT), that leads to production of defective huntingtin protein, which misfolds and accumulates within neurons, thus forming aggerates that affect normal cellular function (Soto, 2003; Williams and Paulson, 2008).”
BackgroundNLRP3 inflammasome activation drives tau pathology
Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., et al. (2019) · Nature · doi:10.1038/s41586-019-1769-z · Cited by 1,487
Inflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355
Unified Polymerization Mechanism for the Assembly of ASC-Dependent Inflammasomes
Lu, A., Magupalli, V. G., Ruan, J., Yin, Q., Atianand, M. K., Vos, M. R., Schröder, G. F., Fitzgerald, K. A., Wu, H., & Egelman, E. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.008 · Cited by 1,353
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112
Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome
Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., & Zhou, R. (2015) · Cell · doi:10.1016/j.cell.2014.11.047 · Cited by 1,014
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983 · cited 1×
“ASC-deficient APP/PS1 mice, as well as those administered with anti-ASC antibody, were able to block the increase in Aβ pathology (Figure 2) (Venegas et al., 2017).”
BackgroundInnate immune memory in the brain shapes neurological disease hallmarks
Wendeln, A.-C., Degenhardt, K., Kaurani, L., Gertig, M., Ulas, T., Jain, G., Wagner, J., Häsler, L. M., Wild, K., Skodras, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0023-4 · Cited by 956 · cited 1×
“Using the APP23 murine AD model, which develops insoluble amyloid plaques at 6 months of age, subcutaneous injection of a low dose of LPS at 3 months of age increased the number of amyloid plaques at 6 months, whereas a 4 x dose of LPS decreased the number of plaques, confirming that peripheral immune stimuli can caus…”
MethodInflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W. H., Mao, X., et al. (2017) · Nature · doi:10.1038/nature22815 · Cited by 866
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791 · cited 1×
“In PD, activated microglia have been found in the SN, and also in more widespread subcortical and cortical regions (McGeer et al., 1988; Imamura et al., 2003; Kouli et al., 2020), and are implicated in neuronal toxicity, via secretions of inflammatory cytokines as well as inducing astrocytes to release neurotoxic elem…”
BackgroundRevisiting the Mechanisms of CNS Immune Privilege
Louveau, A., Harris, T. H., & Kipnis, J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.006 · Cited by 682 · cited 1×
“Furthermore, the central nervous system (CNS) has, until relatively recently, been considered an immune privileged site; however, the discovery of a functional meningeal lymphatic system, that allows movement of cerebrospinal fluid (CSF) to the cervical lymph nodes, has challenged this view and further emphasised the…”
BackgroundNon-motor symptoms in Parkinson's disease
Pfeiffer, R. F. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.004 · Cited by 644
Colonic inflammation in Parkinson's disease
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.-M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.007 · Cited by 627
Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies
Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., & de Bernard, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055375 · Cited by 585
Parkinson’s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation
Matheoud, D., Sugiura, A., Bellemare-Pelletier, A., Laplante, A., Rondeau, C., Chemali, M., Fazel, A., Bergeron, J. J., Trudeau, L.-E., Burelle, Y., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.039 · Cited by 582 · cited 1×
“Mitochondrial dysfunction, such as reduced activity of mitochondrial electron transport chain complex I, mutations in mitochondrial quality control genes, and mtDNA disturbances has been implicated in the pathogenesis of PD (Bose and Beal, 2016; Matheoud et al., 2016; Antonyová et al., 2020).”
BackgroundDempsey, C., Rubio Araiz, A., Bryson, K. J., Finucane, O., Larkin, C., Mills, E. L., Robertson, A. A. B., Cooper, M. A., O'Neill, L. A. J., & Lynch, M. A. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.12.014 · Cited by 571
The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
Saresella, M., La Rosa, F., Piancone, F., Zoppis, M., Marventano, I., Calabrese, E., Rainone, V., Nemni, R., Mancuso, R., & Clerici, M. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0088-1 · Cited by 489
Homeostasis-altering molecular processes as mechanisms of inflammasome activation
Liston, A., & Masters, S. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.151 · Cited by 459 · cited 1×
“The NLRP3 inflammasome is a multimeric protein complex, which assembles in response to homeostasis-altering molecular patterns (HAMPs), pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), and functions as a centrally important component of the innate immune system (Figure 2…”
BackgroundShaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31450 · Cited by 433 · cited 2×
“It is likely that in AD, the increase in IL-1β is a chronic process which develops over months/years (Shaftel et al., 2007).”
BackgroundLee, E., Hwang, I., Park, S., Hong, S., Hwang, B., Cho, Y., Son, J., & Yu, J.-W. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0124-5 · Cited by 431
Han, X., Sun, S., Sun, Y., Song, Q., Zhu, J., Song, N., Chen, M., Sun, T., Xia, M., Ding, J., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596481 · Cited by 408
Ghosh, S., Wu, M. D., Shaftel, S. S., Kyrkanides, S., LaFerla, F. M., Olschowka, J. A., & O'Banion, M. K. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4361-12.2013 · Cited by 390
Liu, J., & Wang, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01005 · Cited by 376
Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., & Vinters, H. V. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00994.x · Cited by 307
Extracellular mutant SOD1 induces microglial‐mediated motoneuron injury
Zhao, W., Beers, D. R., Henkel, J. S., Zhang, W., Urushitani, M., Julien, J., & Appel, S. H. (2010) · Glia · doi:10.1002/glia.20919 · Cited by 288
The choreography of neuroinflammation in Huntington's disease
Crotti, A., & Glass, C. K. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.007 · Cited by 276
Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., Lanté, F., & Buisson, A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4261-13.2014 · Cited by 272 · cited 1×
“Multiple reports show Aβ-induced synaptic dysfunction involving the tau-Fyn axis (Larson et al., 2012; Um et al., 2012; Um and Strittmatter, 2013; Frandemiche et al., 2014; Nygaard, 2018); specifically binding of Aβ oligomers to the cellular prion protein (PrP) on the surface of neurons directly activates Fyn kinase,…”
BackgroundWang, W., Nguyen, L. T. T., Burlak, C., Chegini, F., Guo, F., Chataway, T., Ju, S., Fisher, O. S., Miller, D. W., Datta, D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610099113 · Cited by 270
Sheng, J. G., Ito, K., Skinner, R. D., Mrak, R. E., Rovnaghi, C. R., van Eldik, L. J., & Griffin, W. S. T. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00104-2 · Cited by 269
TDP-43 activates microglia through NF-κB and NLRP3 inflammasome
Zhao, W., Beers, D. R., Bell, S., Wang, J., Wen, S., Baloh, R. H., & Appel, S. H. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.07.019 · Cited by 241
Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease
Combrinck, M. I., Perry, V. H., & Cunningham, C. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00030-1 · Cited by 231
Fan, Z., Pan, Y.-T., Zhang, Z.-Y., Yang, H., Yu, S.-Y., Zheng, Y., Ma, J.-H., & Wang, X.-M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1670-6 · Cited by 228
Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice
DiCarlo, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00292-5 · Cited by 223
Pellegrini, C., Antonioli, L., Calderone, V., Colucci, R., Fornai, M., & Blandizzi, C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101806 · Cited by 174
Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis
Italiani, P., Carlesi, C., Giungato, P., Puxeddu, I., Borroni, B., Bossù, P., Migliorini, P., Siciliano, G., & Boraschi, D. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-94 · Cited by 103
Ojala, J. O., Sutinen, E. M., Salminen, A., & Pirttilä, T. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.09.012 · Cited by 102 · cited 1×
“The loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation, a phenomenon which could be attributed to IL-18, a known inducer of kinases, Cdk5 and glycogen synthase kinase-3β (GSK-3β), which are involved in the hyperphosphorylation of tau (Ojala et al., 2008).”
BackgroundCraft, J. M., Watterson, D. M., Hirsch, E., & Van Eldik, L. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-15 · Cited by 96
Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice
Debye, B., Schmülling, L., Zhou, L., Rune, G., Beyer, C., & Johann, S. (2018) · Brain Pathology · doi:10.1111/bpa.12467 · Cited by 81
Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease
Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Zetterberg, H., & Wild, E. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163479 · Cited by 79 · cited 2×
“Several oxidative stress and inflammatory markers are raised in the serum of patients with HD, including CRP, GM-CSF, TNF, IL-1β, IL-6 and IL-8, strongly suggesting an inflammatory phenotype in this neurological disorder (Björkqvist et al., 2008; Sánchez-López et al., 2012; Chang et al., 2015; Politis et al., 2015; Ro…”
BackgroundEnduring Changes in Neuronal Function upon Systemic Inflammation Are NLRP3 Inflammasome Dependent
Beyer, M. M. S., Lonnemann, N., Remus, A., Latz, E., Heneka, M. T., & Korte, M. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0200-20.2020 · Cited by 55
Kadhim, H., Deltenre, P., Martin, J.-J., & Sébire, G. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2015.11.022 · Cited by 54 · cited 1×
“, 2017), and elevated in-situ expression of NLRP3, activated caspase-1 and IL-18 have been identified in post-mortem brain samples from sALS patients; however, it is unclear whether this is significant as they were compared to a single non-ALS counterpart (Kadhim et al., 2016).”
BackgroundPro- and anti-inflammatory cytokines in the CSF of patients with creutzfeldt-jakob disease.
Stoeck, K., Bodemer, M., & Zerr, I. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.10.008 · Cited by 49 · cited 1×
“In line with this, increased levels of inflammatory cytokines including IL-8, CCL2, TGFβ, TNF and IL-1β have been found in the CSF of sporadic CJD cases (Sharief et al., 1999; Van Everbroeck et al., 2002; Stoeck et al., 2006; Stoeck et al., 2014), with increased IL-1β levels correlating with the number of activated mi…”
BackgroundRole of mtDNA disturbances in the pathogenesis of Alzheimer’s and Parkinson’s disease
Antonyová, V., Kejík, Z., Brogyányi, T., Kaplánek, R., Pajková, M., Talianová, V., Hromádka, R., Masařík, M., Sýkora, D., Mikšátková, L., et al. (2020) · DNA Repair · doi:10.1016/j.dnarep.2020.102871 · Cited by 45
Cited by
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Solving neurodegeneration: common mechanisms and strategies for new treatments
Wareham, L. K., Liddelow, S. A., Temple, S., Benowitz, L. I., Di Polo, A., Wellington, C., Goldberg, J. L., He, Z., Duan, X., Bu, G., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00524-0 · Cited by 324
Palanisamy, C. P., Pei, J., Alugoju, P., Anthikapalli, N. V. A., Jayaraman, S., Veeraraghavan, V. P., Gopathy, S., Roy, J. R., Janaki, C. S., Thalamati, D., et al. (2023) · Theranostics · doi:10.7150/thno.83066 · Cited by 165
“disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [1].”
BackgroundMoraes, C. A., Hottz, E. D., Dos Santos Ornellas, D., Adesse, D., de Azevedo, C. T., d’Avila, J. C., Zaverucha-do-Valle, C., Maron-Gutierrez, T., Barbosa, H. S., Bozza, P. T., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03067-z · Cited by 43
Ayyubova, G., & Madhu, L. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04758-z · Cited by 23
Metadata
- Authors
- Holbrook, J. A., Jarosz-Griffiths, H. H., Caseley, E., Lara-Reyna, S., Poulter, J. A., Williams-Gray, C. H., Peckham, D., & McDermott, M. F.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-10
- Volume
- 12
- Pages
- 643254-643254
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3133822785
- Cited by
- 194
- References
- 63
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.